Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
OwnerLorne Brandesinventor
Life of this patent
Estimating the term…
Abstract
An improved adjuvant treatment of stage I or II breast cancer in which patients are administered a chemotherapeutic agent active in breast cancer is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of the chemotherapeutic agent. Such pretreatment is expected to lead to longer overall survival for patients who have received no prior chemotherapy or no prior treatment type (chemotherapy, radiotherapy and/or hormone treatment) or estrogen receptor-negative tumors.
Claims21
A method of adjuvant chemotherapy in human patients with stage I or II breast cancer, which comprises, following surgical removal of tumor:
- (a) first administering to said patients at least one diphenyl compound of the formula:
- wherein X and Y are each fluorine, chlorine or bromine, Z is an alkylene group of 1 to 3 carbon atoms or ═C═O, or the phenyl groups are joined to form a tricyclic ring, o and p are 0 or 1, R1 and R2 are an alkyl each group containing 1 to 3 carbon atoms or are joined together to form a heterocyclic ring with the nitrogen atom and n is 1, 2 or 3, or pharmaceutically-acceptable salts thereof, and
- (b) following sufficient time to permit inhibition of binding of intracellular histamine, subsequently administering to the patient a chemotherapeutic agent active in breast cancer.
A method of achieving enhanced survival in human patients with stage I or II breast cancer, which comprises:
- (a) selecting for chemotherapy treatment patients who have had no prior chemotherapy treatment or any previous treatment type or estrogen receptor-negative tumors, and
- (b) subject said selected patients to chemotherapy treatment for a plurality of cycles at predetermined intervals, each said cycle comprising:
- (i) first administering to said selected patients at least one diphenyl compound of the formula:
- wherein X and Y are each fluorine, chlorine or bromine, Z is an alkylene group of 1 to 3 carbon atoms or ═C═O, or the phenyl groups are joined to form a tricyclic ring, o and p are 0 or 1, R1 and R2 are each an alkyl group containing 1 to 3 carbon atoms or are joined together to form a heterocyclic ring with the nitrogen atom and n is 1, 2 or 3, or pharmaceutically-acceptable salts thereof, and
- (ii) following sufficient time to permit inhibition of binding of intracellular histamine, subsequently administering to the patient a chemotherapeutic agent active in breast cancer.
Dependencies are inferred from the claim text.